chevron_leftBack
As of 13 June 2026, LB Pharmaceuticals Inc. has a market cap of $877.19M USD, ranking #11481 globally and #2240 in the United States.
It ranks #1041 in the Healthcare sector, and #390 in the Drug Manufacturers - General industry.
Key Stats
Market Cap
$877.19MUSD
Enterprise Value
$590.71MUSD
EBITDA (TTM)
-$29.18MUSD
Net Income (TTM)
-$25.21MUSD
PB Ratio
2.6
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Heather Turner
open_in_new
Employees
27
Founded
2015
IPO
11 Sep 2025
Website
lbpharma.us
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -2.5% | -3.2% | 29% | 45% | 86% | 50% |
News
Loading...
LBRX Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
LBRX
LB Pharmaceuticals Inc
ISIN: US50180M1080
Shares Out.:
Shares Outstanding:
28.677M1
Shares Float:
20.765M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
30.59 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About LB Pharmaceuticals Inc.
LB Pharmaceuticals Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. Its lead product is LB-102, a small molecule oral product, which is in Phase 3 clinical trial for the treatment of acute schizophrenia; completed Phase 2 clinical trial for the treatment of bipolar I depression; adjunctive treatment of MDD; and in pre-clinical stage for the treatment of LAI formulation. The company was incorporated in 2015 and is headquartered in New York, New York.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: LLY
|
$761.68B
87K%
|
38.1
|
|
NYSE: JNJ
|
$547.28B
62K%
|
26.4
|
|
NYSE: ABBV
|
$360.63B
41K%
|
97.4
|
|
NYSE: MRK
|
$274.03B
31K%
|
15.1
|
|
NYSE: PFE
|
$149.38B
17K%
|
19.5
|
|
NYSE: BMY
|
$117.58B
13K%
|
16.8
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
SIX: RO
|
$321.52B
37K%
256.25B CHF
|
19.9
|
|
LSE: AZN
|
$288.84B
33K%
215.59B GBP
|
27.6
|
|
SIX: NOVN
|
$274.65B
31K%
218.9B CHF
|
20.5
|
|
CPH: NOVO-B
|
$181.82B
21K%
1.18T DKK
|
11.5
|
|
EPA: SAN
|
$110.1B
12K%
95.26B EUR
|
19.9
|
|
LSE: GSK
|
$108.46B
12K%
80.96B GBP
|
14.6
|
chevron_leftBack